One of the key issues and perspectives we outlined in our recent State of the Life Sciences Industry guide was President Trump’s intention to reform the Food and Drug Administration (FDA) through the elimination or significant modification of regulations. Part of his recipe for reforming the FDA included bringing in a new head of the FDA, one who shares similar views.
Just yesterday, the Senate confirmed (57 to 42) Dr. Scott Gottlieb, President Trump’s original choice, as the next commissioner of the FDA. If you take Dr. Gottlieb’s record into consideration, his confirmation will likely sit very well with executives in the life sciences industry. He has expressed tremendous interest in bringing new and generic pharmaceutical products to the market faster by getting rid of unnecessary regulations. His impact should help increase competition and bring drug prices down.
